作者：徐铭泽，叶锦宁，袁凯涛，陈创奇，蔡世荣，马晋平

单位：中山大学附属第一医院 胃肠外科中心，广东 广州 510080

Authors: Xu Mingze, Ye Jingning, Yuan Kaitao, Chen Chuangqi, Cai Shirong, Ma Jinping

Unit: Department of Gastrointestinal Surgery, the First Affiliated Hospital of Sun Yat -Sen University, Guangzhou 510080, Guangzhou, China

摘要：

目的 回顾性研究β-1, 3-N-乙酰氨基葡糖转移酶6 (B3GNT6)在结直肠癌患者临床样本中表达的临床意义。方法 选取2012年1月至2014年12月中山大学附属第一医院诊治的154例结直肠癌患者的临床病理资料及随访资料。应用免疫组织化学法检测B3GNT6蛋白在肿瘤组织中的表达情况,经过病理玻片扫描仪数字化处理后,借助Qupath软件对阳性区域进行评分,并用X-tile软件选择合适的截断值,应用卡方检验分析B3GNT6蛋白表达差异与临床病理参数的相关性,Kaplan-Meier法分析B3GNT6蛋白表达与患者预后的相关性。结果 154例患者年龄(59.8±12.8)岁,男女比例为1.26∶1.00。Qupath软件对癌组织进行H-score评分后,X-tile软件计算出H-score最佳截断值为57.44,根据B3GNT6表达情况将所有患者分为B3GNT6低表达组(104例)和高表达组(50例)。B3GNT6低表达与淋巴结转移(P=0.012)、TNM分期(P=0.012)有关。Kaplan-Meier法分析发现B3GNT6高表达组患者预后较好(P=0.0026);单因素及多因素Cox回归分析提示B3GNT6表达是评价结直肠癌患者预后的独立危险因素(HR=0.295,95%CI:0.137～0.634,P=0.002)。结论B3GNT6可能作为结直肠癌患者预后评估的生物标志物。

关键词：B3GNT6；结直肠癌；免疫组织化学；预后

Abstract：

Objective To analyze retrospectively the clinicopathological features and survival analysisof β-1,3-N-acetylglucosaminyltransferase 6 （B3GNT6） in patients with colorectal cancer. Method In this study, a total of 154 patients who were diagnosed with colorectal cancer and completed follow-up in the Gastrointestinal Surgery Center in our hospital from January 2012 to December 2014 were selected. The expression of B3GNT6 protein in tumor tissue was detected by immunohistochemistry. After digital processing by pathological slide scanner, the positive area was scored by the H - score scoring system of Qupath software, and the appropriate cut -off value was selected by X -tile software. Finally, we analyzed the relationship between B3GNT6 and pathological characteristics and survival prognosis. Result The mean age of the 154 patients was（59.8±12.8）years, and the male-to-female ratio was 1.26:1. After the H-Score of cancer tissue was scored by Qupath software, the best cut -off value of H -Score which was calculated by X-tile software was 57.44, so there were 104 patients with low expression of B3GNT6 and 50 patients with high expression of B3GNT6. Low expression of B3GNT6 was associated with lymph node metastasis（P=0.012）and TNM stage（P=0.012）. No statistically significant correlation was found between the expression of B3GNT6 and patients' gender, age, tumor infiltration degree, tumor length, pathological type, tumor differentiation and distant metastasis（P>0.05）. The survival curve showed that B3GNT6 was significantly correlated with tumor prognosis（P=0.0026）; univariate and multivariate Cox regression indicated that B3GNT6 expression wascorrelated with patient survival and prognosis. Conclusion Compared with normal intestinal mucosa, B3GNT6 is relatively low-expressed in colorectal cancer; In colorectal cancer patients, the high -expression group has a longer survival time than the low-expression group, indicating that B3GNT6 can be used as an independent prognostic factor in tumors.

Key Words: B3GNT6; Colorectal cancer; Immunohistochemistry; Survival prognosis